SGLT2 inhibitors versus GLP-1 receptor agonists demonstrate differing effectiveness on cardiovascular and cerebrovascular outcomes in type 2 diabetes patients based on baseline CVD status.
Absolute Event Rate: 0% vs 0%
OPINION article Front. Cardiovasc. Med., 06 September 2022Sec. Cardiovascular Therapeutics Volume 9 - 2022 | https://doi.org/10.3389/fcvm.2022.1011535
Du et al. (Tue,) reported a other. SGLT2 inhibitors versus GLP-1 receptor agonists demonstrate differing effectiveness on cardiovascular and cerebrovascular outcomes in type 2 diabetes patients based on baseline CVD status.